Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: The disclosed technology relates to determining a period in which a non-urgent RRM update should be deferred. The method may comprise applying a first update to an existing configuration of the plurality of wireless access points in the network based on an analysis of telemetry received from the plurality of wireless access points received over a period spanning at least two busy periods. The method may further comprise applying a second update that modifies the first preferred network configuration based on an analysis of telemetry received during the first busy period. The method may further comprise applying a maintenance update to the tweaked network configuration based on telemetry received during the next busy period.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: The disclosed technology relates to determining a period in which a non-urgent RRM update should be deferred. The method may comprise applying a first update to an existing configuration of the plurality of wireless access points in the network based on an analysis of telemetry received from the plurality of wireless access points received over a period spanning at least two busy periods. The method may further comprise applying a second update that modifies the first preferred network configuration based on an analysis of telemetry received during the first busy period. The method may further comprise applying a maintenance update to the tweaked network configuration based on telemetry received during the next busy period.

Abstract: Methods, devices, and systems are described for closed-loop neuromodulation for control of a physiological state. The system includes an energy application system, a user device, a sensor, and a controller. The controller may be configured to select a state phase based on an engagement component. The controller may be configured to prompt at least one of the user device to present a cue to the subject or the energy application system to apply the electrical stimulation to the subject based on the selected state phase. The controller may be configured to measure the set of physiological reactions induced by the selected state phase. The controller may determine a subject bio-psychiatric therapeutic trajectory based on the measured set of physiological reactions from the subject, the subject bio-psychiatric therapeutic trajectory generated by mapping the set of physiological reactions from the subject to the state phase.

Abstract: A system and method are provided for automatically applying configuration recommendations to a wireless network. Configuration recommendations are received from an artificial intelligence (AI) radio resource management (RRM) recommendation engine, and an auto-pilot functionality automatically applies some (or all) of the recommendations to the network, reducing the network administrator's workload. The wireless network receives user inputs for timing, RF frequencies, zones (e.g., building and RF groups therein), risk tolerances, etc. that control configuration policies for how the configuration recommendations are automatically applied to the wireless network. User inputs can be received through a GUI that organizes the types of configuration recommendations into sets (or categories) and associates these sets with respective conditions controlling if/when the respective sets are automatically applied to the network.

Abstract: The disclosed technology relates to determining a period in which a network is busier relative to other periods. The method may comprise analyzing network utilization data from a network segment of the network. The network utilization data may be collected over a first duration. The method may further comprise of determining, from the network utilization data, a baseline network utilization. The baseline network utilization may be a persistent quantification of network utilization present throughout the first duration. The method may further comprise identifying at least a reoccurring period that is characterized by network utilization data indicating consecutive network utilization that is above the baseline network utilizations; and configuring a network controller to designate the at least the reoccurring period as a busy period.

Abstract: The disclosed technology relates to determining a period in which a non-urgent RRM update should be deferred. The method may comprise applying a first update to an existing configuration of the plurality of wireless access points in the network based on an analysis of telemetry received from the plurality of wireless access points received over a period spanning at least two busy periods. The method may further comprise applying a second update that modifies the first preferred network configuration based on an analysis of telemetry received during the first busy period. The method may further comprise applying a maintenance update to the tweaked network configuration based on telemetry received during the next busy period.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.

Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.

Abstract: A system and method for non-invasively applying electrical stimulation to target the olfactory bulb and olfactory mucosa. Current is delivered through an optimal montage of electrodes positioned on the lower forehead, nose bridge, and neck posterior for suppressing the progression of disorders or alleviating symptoms caused by olfactory dysfunction such as Alzheimer’s Disease, Parkinson’s Disease, Loss of Consciousness, etc. Electrode placements are proposed depending on application- for instance using only hair free zones for stimulation. This invention was made with government support under Grant R44NS092144 awarded by the National Institutes of Health. The government has certain rights in the invention.

Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGF? and/or LTBP3-TGF?. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF? activation, and treating subjects suffering from TGF?-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF? inhibitor for a subject in need thereof are also provided.

Abstract: Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.

Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.